Nightingale starts a new strategic partnership with 23andMe and launches a pilot
Translation: Original comment published in Finnish on 06/28/2024 at 6:23 pm EEST
The companies pilot Nightingale Health's Remote Health Check service with a group of 23andMe consumer members. If the pilot succeeds, we estimate that Nightingale’s service can be integrated into 23andMe’s subscription services. The partnership offers Nightingale a potential route to the US consumer market, to which it has not had a clear path so far. 23andMe is an internationally well-known player in genetic testing, and we believe that this partnership is another good sign of the attractiveness of Nightingale’s technology.
Serving consumers with a partnership model (B2B2C) has been one of the segments Nightingale has pursued in its strategy. Opening this segment in the US is, of course, another good sign of the company’s ability to implement its strategy. If successful, the partnership can also bring significant revenue growth to Nightingale. However, we do see direct healthcare customers (B2B/B2G) as more important for the company’s business growth. Nightingale has released a lot of positive news for the healthcare segment, most recently earlier on Friday.
Login required
This content is only available for logged in users
Nightingale Health
Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.
Read more on company pageKey Estimate Figures10.05.
2023 | 24e | 25e | |
---|---|---|---|
Omsättning | 4,2 | 4,7 | 8,7 |
tillväxt-% | 80,80 % | 12,78 % | 85,00 % |
EBIT (adj.) | −18,5 | −17,8 | −17,6 |
EBIT-% | −442,95 % | −377,50 % | −201,86 % |
EPS (adj.) | −0,30 | −0,27 | −0,27 |
Utdelning | 0,00 | 0,00 | 0,00 |
Direktavkastning | |||
P/E (just.) | - | - | - |
EV/EBITDA | 0,77 | - | - |